|
|
||||||||
Ann Thorac Surg 2002;74:2082-2087
© 2002 The Society of Thoracic Surgeons
LVEF
30%): a comparison of bypass grafting and percutaneous intervention
a Department of Surgery and Cardiology, New Orleans, Louisiana, USA
Accepted for publication July 26, 2002.
* Address reprint requests to Dr Van Meter, Division of Thoracic Cardiovascular Surgery, Department of Surgery, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, LA 07121; USA.
e-mail: cvanmeter{at}ochsner.org
Presented at the Thirty-eighth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 2830, 2002.
| Abstract |
|---|
|
|
|---|
METHODS: We conducted a single-center observational study of 117 consecutive patients who had severe LV dysfunction (15%
LV ejection fraction
30%) and underwent either coronary artery bypass grafting (CABG, n = 69) or percutaneous revascularization (n = 48) between 1992 and 1997.
RESULTS: The CABG group was younger (62 versus 67 years, p = 0.026), and fewer previous bypasses (7% versus 40%, p < 0.0001) and fewer prior percutaneous revascularizations (16% versus 42%, p = 0.0019) were noted. More vessels were revascularized (3 ± 0.8 versus 1.5 ± 0.7, p < 0.0001), and revascularization was more complete by CABG (84% versus 48%, p < 0.0001). Morbidity and mortality at 30 days were similar, and there was no significant difference in 3-year survival (73% versus 67%), although 3-year cardiac event-free survival (52% versus 25%, p = 0.0011) and 3-year target vessel revascularizationfree survival (71% versus 41%, p < 0.0001) were significantly better in the CABG group, and LV ejection fraction was significantly improved after CABG. In the subgroup of patients 65 years of age or older and those without proximal left anterior descending coronary artery lesions, significant benefit of CABG in cardiac event-free and target vessel revascularizationfree survival disappeared.
CONCLUSIONS: We found that in clinically selected patients with severe ventricular dysfunction, CABG compared with percutaneous revascularization achieves more complete revascularization, improved LV function, fewer cardiac events, and fewer target vessel revascularizations, but does not affect mid-term survival. A prospective controlled trial with defined criteria for treatment assignment is warranted to confirm our results regarding the two revascularization strategies in patients with severe LV dysfunction.
| Introduction |
|---|
|
|
|---|
On the other hand, patients with LV dysfunction once were considered poor candidates for percutaneous revascularization (PCI), because acute closure of lesions after balloon dilatation might result in death if the treated coronary artery supplied the only remaining viable myocardium. Recent advances in interventional cardiology have allowed angioplasty and intracoronary stent placement in patients with multivessel disease. Intracoronary stents have reduced the need for both emergency CABG and subsequent revascularization procedures [6]. Rotational coronary atherectomy has expanded interventional options, and calcified or long lesions can be treated [7]. The advances in technology have improved the efficacy and safety of PCI in patients with depressed LVEF [8].
Because most randomized clinical trials comparing CABG and PCI exclude patients with low LVEF [9], little information exists clarifying the optimum revascularization strategy in patients with severe LV dysfunction.To examine the comparative benefits and risk of CABG and PCI in patients with severe LV dysfunction, this retrospective study was conducted.
| Patients and methods |
|---|
|
|
|---|
Procedures
Patients who were selected for operation underwent CABG with full sternotomy and standard cardiopulmonary bypass. Patients were cooled down to 32°C, and antegrade or antegrade and retrograde cold-blood cardioplegia were given for cardioplegic arrest. Percutaneous revascularization was performed using standard techniques. In these patients preoperative and postoperative variables were investigated by reviewing the clinical chart, and follow-up was conducted between November 1999 and February 2000 by telephone interviews and review of outpatient records.
Definitions
Unstable angina was defined as anginal pain accelerating in frequency and severity that necessitated heparin or nitroglycerin infusion. The number of diseased vessels was defined as the number of the three major coronary perfusion territories (anterior, lateral, and inferoposterior). Thirty-day mortality included noncardiac death, but long-term mortality excluded noncardiac death. Postoperative dialysis was defined as dialysis that was initiated for acute renal failure after the procedure. Patients who needed intubation for respiratory support for more than 3 days defined respiratory failure. A cerebrovascular accident was defined as a focal or global neurologic deficit confirmed by a neurologist. A cardiac event was defined as recurrent angina, myocardial infarction, or congestive heart failure that required hospitalization.
Statistical analysis
Data were analyzed with computer software (StatView, version 5, Abacus Concepts, Berkeley, CA). Values are expressed as mean ± standard deviation. Fishers exact test was used for categorical variables, and the Mann-Whitney U test was used to compare continuous variables. The Wilcoxon signed rank test was used to compare EF before and after procedures. Survival curves were generated using Kaplan-Meier methods, and the comparison between survival distributions was made by log rank test. The Cox proportional hazard model is used to calculated an adjusted hazard ratio of PCI patient risk to CABG patient risk. The Cox model was adjusted by patient severity of illness, including number of diseased coronary vessels, presence of New York Heart Association class III or IV heart failure and history of previous revascularization. A p value less than 0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
Cardiopulmonary bypass was used in 1 patient for complicated PCI, and 2 patients (4%) needed emergency CABG after PCI. The CABG group hospital stay was slightly longer than that of the PCI group, but there was no significant difference in morbidity and mortality within 30 days after procedure (Table 2). Five operative deaths occurred in the CABG group. One patient was unable to be weaned from cardiopulmonary bypass, 2 patients died of low output syndrome, 1 patient died of ventricular tachycardia, and 1 patient died of sepsis secondary to pneumonia. Four patients died after PCI. Three patients died of ventricular tachycardia, and 1 patient died of low output syndrome.
|
Ninety-one percent of CABG patients and 90% of PCI patients were followed completely. The PCI group was followed for 38 ± 14 months, which is statistically shorter than the CABG group (51 ± 19 months), because we have fewer PCI patients between 1992 and 1994 (25 CABG patients versus 13 PCI patients) and more patients with low EF were assigned to PCI between 1995 and 1997 (44 CABG patients versus 35 PCI patients). Cardiac eventfree survival curves are shown in Figure 1A. In the CABG group 26 patients needed rehospitalization because of angina (3 patients), myocardial infarction (4 patients), and congestive heart failure (19 patients). In the PCI group 28 patients needed rehospitalization because of angina (17 patients), myocardial infarction (2 patients), and congestive heart failure (9 patients). Cardiac eventfree survival rate at 3 years was 52% in the CABG group and 25% in the PCI group, and there was a significant difference in cardiac eventfree survival curves (p = 0.0011). Target vessel revascularization (TAVER)free survival curves are shown in Figure 1B. In the CABG group 1 patient underwent redo CABG, 3 patients underwent PCI, and 1 patient underwent heart transplantation. In the PCI group 14 patients underwent repeat PCI, 4 patients needed CABG including two emergency CABGs, and 1 patient underwent heart transplantation. The TAVER-free survival rate at 3 years was 71% in the CABG group and 41% in the PCI group, and there was a significant difference in the TAVER-free survival curves (p < 0.0001). Survival curves are shown in Figure 1C. There was no significant difference in survival curves (p = 0.3944), and survival rate at 3 years was 73% in the CABG group and 67% in the PCI group.
|
|
| Comment |
|---|
|
|
|---|
LVEF
30%), although CABG achieved more complete revascularization, improved LVEF, and reduced cardiac events, and TAVERs. The completeness of revascularization has been found to be an important predictor of long-term survival and functional status after CABG [10]. However, a recent randomized study demonstrated that incomplete revascularization by PCI in patients with multivessel disease and preserved LVEF does not compromise hospital mortality and long-term survival, although freedom from angina and repeat revascularization at 5 years were significantly lower than the patients randomized to CABG [11]. Our results suggest that incomplete revascularization by PCI may salvage patients even with severe LV dysfunction and prolong intermediate survival to the extent that CABG can achieve with complete revascularization. However, patients must be followed closely and receive subsequent treatment and intervention as necessary. It is interesting to see similar results in a randomized study that compared CABG and PCI in patients with preserved LV function. There were no significant differences in survival in any of the nine randomized trials that compared CABG and PCI, but these trials showed that the need for TAVER was significantly higher in PCI, and most trials found that CABG resulted in greater freedom from angina [9]. There is one nonrandomized study that compared CABG and PCI in patients with LVEF less than 40% [12]. They showed significantly improved cardiac eventfree survival and freedom from TAVER, but no significant difference in survival between CABG and PCI. Because our study as well is not randomized, the differences in age, extent of coronary artery disease and heart failure, and completeness of revascularization between groups bias the result. Because two nonrandomized studies demonstrated no difference in survival between these revascularization strategies, a prospective controlled trial with defined criteria for treatment assignment is necessary and warranted to confirm our results regarding two revascularization strategies in patients with severe LV dysfunction.
Analysis of adjusted hazard ratios of patient death and cardiac event, and patient death and TAVER, showed significant benefits of CABG in patients younger than 65 years of age or patients with significant proximal LAD lesions. This result suggests that these two subgroups may be appropriate criteria for surgical revascularization in a future prospective controlled trial.
A recent study has indicated that high-risk patients including LV dysfunction have a benefit from off-pump CABG [13]. Although not used in our study, application of new technology such as off-pump CABG and minimum invasive direct coronary artery bypass grafting in this patient group may reduce myocardial injury and systemic inflammatory response secondary to cardiopulmonary bypass and cardioplegic arrest. Although intracoronary stenting was used in 67% of our patients, new refinements in stent design and adjunctive pharmacologic therapy are reducing event of restenosis, which is the greatest weakness of PCI and will improve patient outcomes [14]. These evolving technologies will have a great impact on both revascularization strategies.
Despite advances in the medical treatment for coronary artery disease and heart failure, coronary artery disease with severe LV dysfunction ultimately has a poor prognosis. We and other authors suggested that CABG can be an alternative in patients waiting for heart transplantation, because ventricular dysfunction may be reversible by restoration of coronary perfusion, if viable hibernating myocardium is present [15]. Our current data demonstrated 1-year survival of 84% after CABG and 73% after PCI which are comparable to the survival after transplantation (86%) and survival on the waiting list (80%) [16]. Considering the shortage of donor hearts and the long waiting list, CABG and PCI may be alternatives to heart transplantation in selected patients or a bridge to heart transplantation.
In conclusion, this observational study suggests that in clinically selected patients with severe LV dysfunction, a strategy of CABG compared with PCI achieves more complete revascularization, improved LV function, fewer cardiac events, and fewer TAVERs, but does not affect mid-term survival. A prospective controlled trial with defined criteria for treatment assignment and long-term follow-up is warranted to confirm our results regarding two revascularization strategies in the patients with severe LV dysfunction.
| Discussion |
|---|
|
|
|---|
DR TODA: Yes. In this study I remember that in 13 cases they did percutaneous revascularization for vein graft disease. Otherwise they treated native vessels.
DR LISHAN AKLOG (Boston, MA): The time of the study spans a period when the use of stents increased over time. Could you tell us what percentage of patients in the percutaneous revascularization group received a stent and what percentage had simple angioplasty?
DR TODA: In this study 67% of the patients had a coronary stent.
DR JONATHAN HAMMOND (Hartford, CT): I was disappointed to see that survival was essentially the same at 3 years. Did you assess New York Heart Association functional class at 3 years, was improvement noted and sustained, and was there a difference between the two groups?
DR TODA: No, I did not assess the change of the New York Heart Association class in the follow-up; however, we know that the ejection fraction was improved after operation.
DR BRIGITTE R. OSSWALD (Heidelberg, Germany): I think it is a very important thing to stress on those people who really have a severe left ventricular dysfunction; however, I was a bit disappointed about the number of factors you included in your analysis. These people do have a high comorbidity, and I missed something like dialysis dependency and neurologic disorders like stroke, transient ischemic attack, and some more time-related, detailed factors concerning the comorbidity. Do you intend to include some more factors in your analysis?
DR TODA: Yes. Preoperatively we assess the comorbidities, including cerebrovascular accident. As I have shown here, there is no difference in the co-morbidity including cerebrovascular accident.
| References |
|---|
|
|
|---|
40%. Am J Cardiol 1993;71:897-901.[Medline]
This article has been cited by other articles:
![]() |
P. Chareonthaitawee, B. J. Gersh, P. A. Araoz, and R. J. Gibbons Revascularization in Severe Left Ventricular Dysfunction: The Role of Viability Testing J. Am. Coll. Cardiol., August 16, 2005; 46(4): 567 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. McCarron, M. J. Shackcloth, A. D. Grayson, and W. C. Dihmis Left internal mammary artery use in patients with poor left ventricular ejection fraction: a propensity-matched analysis of mid-term survival Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 184 - 188. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |